Novimmune Sells Gamifant And IO Assets To Sobi

Novimmune SA has a sold a newly created vehicle comprising Gamifant (emapalumab) and related assets, two additional immune-oncology candidates and an FDA priority review voucher to Sweden’s Swedish Orphan Biovitrum AB for CHF515m ($519m). The acquisition comes less than a year after Novimmune granted Sobi an exclusive worldwide license for Gamifant. The acquisition fits in Sobi's sweet spot for rebalancing its portfolio and enhancing its immunology activities